<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289987</url>
  </required_header>
  <id_info>
    <org_study_id>CVI-HBV-002-CT1901</org_study_id>
    <nct_id>NCT04289987</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine</brief_title>
  <official_title>A Randomized, Double-blinded, Placebo-controlled, Parallel, Multicenter, Phase 2b Study to Evaluate the Efficacy and Safety of CVI-HBV-002 in Patients With Chronic Hepatitis B Taking Tenofovir Disoproxil Fumarate/Tenofovir Disoproxil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHA Vaccine Institute Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHA Vaccine Institute Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the evaluate and safety of the investigational
      medicinal product CVI-HBV-002.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blinded, placebo-controlled, parallel, multicenter, phase 2b study to
      evaluate the efficacy and safety of CVI-HBV-002 in patients with chronic hepatitis B taking
      Tenofovir disoproxil fumarate/Tenofovir disoproxil
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 19, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Mean Change in HBsAg(log10 IU/mL)</measure>
    <time_frame>at week 48 from baseline</time_frame>
    <description>To evaluate mean changes in serum HBsAg(log 10 IU/mL) for patients treated with CVI-HBV-002 or Placebo at Week 48 versus Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Mean changes in serum HBsAg(log 10 IU/mL)</measure>
    <time_frame>at week 24 from baseline</time_frame>
    <description>To evaluate mean changes in serum HBsAg(log 10 IU/mL) for patients treated with CVI-HBV-002 or Placebo at Week 24 versus Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion assessment of Participants With HBsAg loss</measure>
    <time_frame>at weeks 24 and 48</time_frame>
    <description>To evaluate proportion of subjects with HBsAg loss for patients treated with CVI-HBV-002 or Placebo at Weeks 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion assessment of Participants With HBsAg seroconversion</measure>
    <time_frame>at weeks 24 and 48</time_frame>
    <description>To evaluate proportion of subjects with HBsAg seroconversion for patients treated with CVI-HBV-002 or Placebo at Weeks 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion assessment of Participants With HBeAg loss</measure>
    <time_frame>at Weeks 24 and 48</time_frame>
    <description>To evaluate proportion of subjects with HBeAg loss for HBeAg positive patients treated with CVI-HBV-002 or Placebo at Weeks 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion assessment of Participants With HBeAg seroconversion</measure>
    <time_frame>at weeks 24 and 48</time_frame>
    <description>To evaluate proportion of subjects with HBeAg seroconversion for HBeAg positive patients treated with CVI-HBV-002 or Placebo at Weeks 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of changes in HBV specific T cell immunity</measure>
    <time_frame>at weeks 12 and 24 from baseline</time_frame>
    <description>Immune Response Rate of HBV specific T cell at Weeks 12 and 24 versus Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion assessment of Participants With Virologic breakthrough</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>Proportion of subjects with experiencing virologic breakthrough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence assessment of Treatment-Emergent Adverse Evnent</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Safety and tolerability assessment through incidence of Treatment-Emergent Adverse Evnent after treatment of Investigational Product</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">153</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>CVI-HBV-002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CVI-HBV-002 1.0mL(20ug/dose)
Intramuscular injection at Baseline, Week 2, 4, 8, 12, 16, 20 / total 7 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline Choonwae Inj. 1.0 mL
Intramuscular injection at Baseline, Week 2, 4, 8, 12, 16, 20 / total 7 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CVI-HBV-002, Normal Saline</intervention_name>
    <description>Investigational Product</description>
    <arm_group_label>CVI-HBV-002</arm_group_label>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult between 19 to 60 years of age

          2. Those who have been diagnosed as chronic hepatitis B patients (e.g.HBsAg positive
             detected for 6 months or more)

          3. Started treatment with Tenofovir Disoproxil Fumarate(TDF) or Tenofovir Diproxil(TD),
             oral HBV antiviral agent, for 6 months to 5 years.

          4. HBsAg ≥ 100 IU/mL, HBV DNA ≤ 100 IU/mL at screening

          5. HBV DNA ≤ 2000 IU/mL at screening

          6. ALT ≤ Upper Limit of Normal) x 2 at screening

          7. Ability to understand and sign a written informed consent form, which must be obtained
             prior to initiation of study procedures

        Exclusion Criteria:

          1. Patients with other hepatic disease other than chronic hepatitis B(e.g.,
             hemochromatosis, Wilson disease, alcoholic liver disease, nonalcoholic
             steatohepatitis, alpha-1 antitrypsin deficiency, etc)

          2. If any of the following laboratory tests were found at screening

               -  Total bilirubin &gt; Upper Limit of Normal x 2

               -  Prothrombin time delayed more than 3 seconds than normal

               -  Serum Albumin &lt; 30 g/L (3 g/dL)

               -  Hemoglobin &lt; 9.0 g/dL eGFR &lt; 60 mL/min (Cockcroft-Gault)

               -  Absolute neutrophil count (ANC) &lt; 1.5 x 10^9 /L (1500 /mm3)

               -  Platelet count &lt; 100 x 10^9 /L (100 x 10^3 /mm3)

               -  Serum creatinine &gt; 1.5 mg/dL

               -  Serum amylase &gt; 2 x ULN and Lipase &gt; 2 x ULN

          3. A history of ascites, jaundice, varicoses vein bleeding, hepatic encephalopathy, or
             other signs of liver failure

          4. Treated with oral antiviral agents or interferon therapy other than TDF(or TD)

          5. In case of receiving nephroxic drugs(Aminoglycosides, Amphotericin B, NSAIDs, etc.)
             within 14 days prior to screening

          6. When hepatotoxic drugs(Erythromycin, Ketoconazole, Rifampin, Fluconazole, Dapsone,
             etc.) are administered within 14 days prior to screening

          7. Patients with active bacterial, viral or fungal infections requiring systemic
             treatment

          8. Patients diagnosed with Alpha-fetoprotein (AFP) &gt;50 ng/mL or with Hepatocellular
             Carcinoma (HCC) in screening

          9. Of those who have received immunosuppressive drugs within 6 months prior to screening,
             patients suspected of having decreased immunity by the judgment of the Investigator

         10. Patients who have received high dose (prednisone 20mg or more*) systemic
             corticosteroids for a long period of time(consecutive 14 days or longer) within 3
             months before screening (at the discretion of the investigator in case of local
             corticosteroids)

             * Corresponding to 125 mg of cortisone, 100 mg of hydrocortisone, 20 mg of prednisone,
             16 mg of methylpreprednisolone, 16 mg of triamsynolone, 3 mg of dexamethasone and 2.4
             mg of betametasone.

         11. Patients who have been diagnosed with malignant tumors within 5 years before
             screening, or who have recurred malignant tumors(in case of benign tumors, if the
             Investigator considers that the progress of the clinical trial is not affected during
             the clinical trial)

         12. Organ transplantation recipients

         13. Patients with serious illnesses, such as heart failure, renal failure, and
             pancreatitis, other than liver disease

         14. Patients with a history of serious heart disease (NYHA Functional Class III or IV
             heart failure, myocardial infarction within 6 months, ventricular tachyarrhythmias
             requiring treatment or unstable angina)

         15. Patients with seizure disorders who require anticonvulsant therapy

         16. HbA1c&gt;7.5%

         17. SBP≥140mmHg or DBP≥90mmHg

         18. Patients infected with hepatitis C(HCV), hepatitis D(HDV) or human immunodeficiency
             virus(HIV)

         19. A hypersensitivity or anaphylactic reaction to the components of the clinical trial
             drug or HBV vaccine components

         20. Continued drinking(&gt;21 units/week, 1 unit = 10g of pure alcohol) or alcohol dependence

         21. Pregnancy or breastfeeding, or cannot agree with the approved method of contraception
             of the patient and partner during the clinical trial(e.g., infertility surgery,
             intrauterine contraceptive, oral contraceptive and concomitant use of diaphragm or
             condom, other hormonal delivery systems and concomitant use of diaphragm or condom)

         22. Patients who are concerned about the deterioration of daily function due to mental
             illness or who cannot understand the purpose and method of this trial

         23. Patient who has potential to severe febrile or systemic reaction

         24. Patients who are scheduled to participate in other clinical trials after enrolling in
             this trial, or have participated in other clinical trials within 3 month of enrollment
             in this trial

         25. Others those who are considered to be difficult to perform the clinical trial by the
             judgment of the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gabsoon Noh</last_name>
    <phone>82-31-881-7421</phone>
    <email>gsnoh75@chamc.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chung-ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Dongjak-gu</state>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyung Joon Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Eunpyeong St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Eunpyeong-gu</state>
        <zip>03312</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Si-Hyun Bae</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joon Hyeok Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Guro-gu</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji-Hoon Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bundang CHA General Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sungkyu Hwang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung-Hwan Yoon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Sedaemun-gu</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Do-young Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Suk Lim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soon Chung Hyang University Hospital Seoul</name>
      <address>
        <city>Seoul</city>
        <state>Yongsan-gu</state>
        <zip>04401</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Young Jang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 22, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

